All Work

Vandita Jadeja

Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield

Two healthcare giants, two very different dividend bets: one built on six decades of unbroken raises and a fortress balance sheet, the other dangling a fatter yield while racing to outrun its own blockbuster's…

Vandita Jadeja · 1 month ago

Big Cash, Bigger Ambitions: POET Technologies Eyes 147% Upside

POET Technologies carries a fortress balance sheet, a landmark customer contract, and a Malaysia production ramp finally moving toward real shipments, yet lawsuits, massive dilution, and a sky-high valuation make this one of the…

Vandita Jadeja · 1 month ago

Oracle vs SMCI: Two AI Buildout Bets, One Big Catch

Oracle and Supermicro both crushed earnings on the back of the AI infrastructure boom, but both companies share a problem that could derail the whole story before FY2027 guidance ever gets tested.

Vandita Jadeja · 1 month ago

Johnson & Johnson Nearing 52-Week High: Buy, Sell or Hold?

Johnson & Johnson has surged more than 50% in a year and now sits within striking distance of its 52-week high, but a closer look at the valuation, insider activity, and pipeline pressures raises…

Vandita Jadeja · 2 months ago

The Palantir Bull Case Is Getting Harder to Ignore

Palantir just delivered a quarter that broke every model, and even skeptics are struggling to explain away what the numbers show. Here is why the stock may have further to run than almost anyone…

Vandita Jadeja · 2 months ago

Costco’s Stock Has a Problem: It’s Almost Too Good

Costco runs one of the most airtight business models in retail, yet the stock is going nowhere fast. What happens when a near-perfect company runs out of room to surprise the market?

Vandita Jadeja · 2 months ago

Nvidia’s Next Act: Can NVDA Defy Gravity Again?

NVIDIA just posted 85% revenue growth yet trades 28% below its 52-week high, and Wall Street cannot agree on whether the stock is a bargain or a trap. Three specific catalysts could push shares…

Vandita Jadeja · 2 months ago